| Deal value | $40M |
|---|---|
| Share of market cap | 12.7% |
Key highlights
- Offering of 8,000,000 shares priced at $5.00 per share for $40 million gross proceeds
- Underwriters granted a 30-day option for 1.2 million additional shares
- Proceeds earmarked for general corporate purposes and potential debt repayment
- Lock-up agreements for directors and officers in effect until January 19, 2027
- Expected closing on or about October 22, 2026, subject to customary conditions
What Is the Capital Raise?
Alpha Teknova, Inc. has finalized an agreement to sell 8,000,000 shares of its common stock through an underwritten public offering priced at $5.00 per share. TD Securities and William Blair are leading the transaction as joint book-running managers. The agreement includes a 30-day over-allotment option for underwriters to purchase an additional 1.2 million shares, which could increase gross proceeds by approximately $6 million. The transaction is conducted under a previously filed shelf registration statement on Form S-3 and is scheduled to close on October 22, 2026, contingent on the satisfaction of customary closing conditions.
Use of Proceeds
- Proceeds will support general corporate operations and working capital needs
- Management intends to evaluate the repayment of current outstanding debt obligations
- Capital may be deployed for strategic acquisitions of complementary technologies
- Funds will assist in scaling modular manufacturing platforms for next-generation therapies
- A portion of net proceeds may fund investments in new life science products
Strategic Rationale
The timing of this $40 million raise follows management's preliminary third-quarter 2026 revenue guidance of $12.5 to $12.7 million. By securing fresh equity, the company gains the flexibility to manage its existing credit agreement, which recently carried an outstanding balance of approximately $28.2 million. This infusion of capital addresses the immediate liquidity requirements necessary to sustain the company's 180,000 square feet of state-of-the-art facilities in Hollister, California, while navigating market volatility that has seen the share price adjust to the new offering terms. The move signals a transition toward a more robust balance sheet to support long-term commercialization.
Up 32.8% since our story on 21 Oct: $5.85 when we broke it → $7.77 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $6.80 |
|---|---|
| 20 Oct | $7.39 |
| 21 Oct | $5.85 |
| 22 Oct | $6.15 |
| 23 Oct | $6.42 |
| 26 Oct | $6.59 |
| 27 Oct | $7.11 |
| 28 Oct | $7.86 |
| 29 Oct | $8.09 |
| 30 Oct | $7.36 |
| 2 Nov | $7.01 |
| 3 Nov | $7.34 |
| 4 Nov | $7.37 |
| 5 Nov | $7.88 |
| 6 Nov | $7.81 |
| 9 Nov | $8.55 |
| 10 Nov | $8.73 |
| 11 Nov | $8.62 |
| 12 Nov | $8.29 |
| 13 Nov | $8.21 |
| 16 Nov | $7.77 |
Business Overview
Alpha Teknova specializes in producing critical reagents required for the discovery and commercialization of next-generation therapies, including vaccines and molecular diagnostics. The company provides customized solutions across the life sciences workflow, ranging from Research Use Only (RUO) to Good Manufacturing Practice (GMP) standards. Its product portfolio features high-quality agar plates, microbial culture media, and specialized buffers. Operating with a business model that emphasizes rapid turnaround, the firm typically fills customer orders within a 24 to 48-hour window, supporting diverse clients in the genomics and emerging therapeutic sectors through its modular manufacturing platform.
Financial Context
- Annual revenue for the company reached $40.52 million in the most recent fiscal year
- Quarterly revenue for the current period is guided at approximately $12.5 million
- The Relative Strength Index has dipped to 29.2 following the dilutive share issuance
- Directors and executive officers are bound by lock-up agreements until January 2027
- The current market capitalization stands at roughly $314 million
| Date | Announcement | Amount |
|---|---|---|
| 20 Oct 2026 | Pricing of underwritten public offering of common stockSource: stocktitan.net | $40.0 Million |
| 20 Oct 2026 | Proposed underwritten public offering of common stockSource: stocktitan.net | – |
| 03 Mar 2025 | Second Amended and Restated Credit Agreement debt facilitySource: finquota.com | $28.2 Million |
| Share price | $5.85 |
|---|---|
| Market cap | $314M |
| Revenue (annual) | $41M |
| 1-month price change | -29.86% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Alpha Teknova, Inc. announcing an underwritten public offering of common stock.
Track Alpha Teknova, Inc. live
Get the next Alpha Teknova, Inc. SEC filing seconds after it lands.



